Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information

```
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:16:35 ON 07 AUG 2005

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:16:47 ON 07 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 AUG 2005  HIGHEST RN 858648-31-4
DICTIONARY FILE UPDATES:    5 AUG 2005  HIGHEST RN 858648-31-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10772721.str
```



chain nodes :
10 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 20 21 22 23 24 25
chain bonds :
2-10 8-17 17-18 17-19 18-20
ring bonds :
1-2 1-5 1-6 1-9 2-3 3-4 3-11 4-5 4-14 6-7 7-8 8-9 11-12 12-13 13-14
20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
1-2 1-5 1-6 1-9 2-3 2-10 3-4 3-11 4-5 4-14 6-7 7-8 8-9 11-12 12-13
13-14 17-18 17-19 18-20
exact bonds :
8-17
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25
isolated ring systems :
containing 20 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 17:CLASS 18:CLASS 19:CLASS 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:17:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     27 TO ITERATE

100.0% PROCESSED       27 ITERATIONS                                 14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          229 TO      851
PROJECTED ANSWERS:              56 TO      504

L2           14 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:17:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    418 TO ITERATE

100.0% PROCESSED      418 ITERATIONS                               229 ANSWERS
SEARCH TIME: 00.00.01

L3          229 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.76     161.97

FILE 'CAPLUS' ENTERED AT 16:17:45 ON 07 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 7 Aug 2005 VOL 143 ISS 7
FILE LAST UPDATED: 5 Aug 2005 (20050805/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:158440 CAPLUS
DOCUMENT NUMBER: 140:334323
TITLE: Characterization of the Binding Site for Inhibitors of the HPV11 E1-E2 Protein Interaction on the E2 Transactivation Domain by Photoaffinity Labeling and Mass Spectrometry
AUTHOR(S): Davidson, Walter; McGibbon, Graham A.; White, Peter W.; Yoakim, Christiane; Hopkins, Jerry L.; Guse, Ingrid; Hambly, David M.; Frego, Lee; Ogilvie, William W.; Lavallee, Pierre; Archambault, Jacques
CORPORATE SOURCE: Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Analytical Chemistry (2004), 76(7), 2095-2102
CODEN: ANCHAM; ISSN: 0003-2700
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An indandione-containing class of inhibitors abrogates DNA replication of human papillomavirus (HPV) types 6 and 11 by binding reversibly to the transactivation domain (TAD) of the viral E2 protein and inhibiting its interaction with the viral E1 helicase. To locate the binding site of this class of protein-protein interaction inhibitors, a benzophenone derivative was used to generate an irreversibly labeled E2-TAD polypeptide. The single site of covalent modification of the E2-TAD was identified by proteolytic digestions using trypsin, LysC, and V8 proteases and characterization of the resulting peptides by LC-MS procedures. Through this methodol., the benzophenone attachment point was located at the terminal Me of residue Met101. Evidence further pinpointed the site of photoaffinity attachment to the terminal carbon atom, which is significant in providing a definitive example of the ability to locate photoinduced crosslinking to a polypeptide with atomic resolution using solely mass spectrometric detection. The location of the inhibitor binding site vis-a-vis the Glu39 and Glu100 residues sensitive to mutation for HPV 11 E2-TAD is discussed in relation to the crystal structure of the E2-TAD from the related HPV type 16.
IT 680194-88-1
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(binding site for inhibitors of HPV11 E1-E2 protein interaction on E2 transactivation domain by photoaffinity labeling and mass spectrometry)
RN 680194-88-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-benzoylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:153611 CAPLUS
DOCUMENT NUMBER: 140:357234
TITLE: A series of heterocyclic inhibitors of phenylalanyl-tRNA synthetases with antibacterial activity
AUTHOR(S): Yu, Xiang Y.; Finn, John; Hill, Jason M.; Wang, Zhong G.; Keith, Dennis; Silverman, Jared; Oliver, N.
CORPORATE SOURCE: Department of Medicinal Chemistry, Cubist Pharmaceuticals, Inc., Cambridge, MA, 02139, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1343-1346
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of benzodioxatricycloundecanes was synthesized and evaluated for their ability to inhibit phenylalanyl-tRNA synthetases and act as antibacterial agents. Several analogs have good antibacterial activity against Staphylococcus aureus.
IT 682749-39-9P 682749-46-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of benzodioxatricycloundecanes as phenylalanyl-tRNA synthetases
with antibacterial activity)
RN 682749-39-9 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-4,10-dioxo-2-phenyl-, (2R,3R,3aS,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 682749-46-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(3,4-dichlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-phenyl-, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:124707 CAPLUS
DOCUMENT NUMBER: 140:352268
TITLE: Crystal Structure of the E2 Transactivation Domain of Human Papillomavirus Type 11 Bound to a Protein Interaction Inhibitor
AUTHOR(S): Wang, Yong; Coulombe, Rene; Cameron, Dale R.; Thauvette, Louise; Massariol, Marie-Josee; Amon, Lynn M.; Fink, Dominique; Titolo, Steve; Welchner, Ewald; Yoakim, Christiane; Archambault, Jacques; White, Peter W.
CORPORATE SOURCE: Department of Biological Sciences and Department of Chemistry, Boehringer Ingelheim Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Journal of Biological Chemistry (2004), 279(8), 6976-6985
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Interaction between the E2 protein and E1 helicase of human papillomaviruses (HPVs) is essential for the initiation of viral DNA replication. We recently described a series of small mols. that bind to the N-terminal transactivation domain (TAD) of HPV type 11 E2 and inhibits its interaction with E1 in vitro and in cellular assays. Here we report the crystal structures of both the HPV11 TAD and of a complex between this domain and an inhibitor, at 2.5- and 2.4-Å resolution, resp. The HPV11 TAD structure is very similar to that of the analogous domain of HPV16. Inhibitor binding caused no significant alteration of the protein backbone, but movements of several amino acid side chains at the binding site, in particular those of Tyr-19, His-32, Leu-94, and Glu-100, resulted in the formation of a deep hydrophobic pocket that accommodates the indandione moiety of the inhibitor. Mutational anal. provides functional evidence for specific interactions between Tyr-19 and E1 and between His-32 and the inhibitor. A second inhibitor mol. is also present at the binding pocket. Although evidence is presented that this second mol. makes only weak interactions with the protein and is likely an artifact of crystallization, its presence defines addnl. regions of the binding pocket that could be exploited to design more potent inhibitors.

IT 681294-54-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(structural and biochem. anal. address mol. basis of indandione inhibitor disruption of binding between HPV11 E2 protein transactivation domain and E1 helicase)
RN 681294-54-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 681294-53-1D, complexes with E2 protein
RL: PRP (Properties)
(structural and biochem. anal. address mol. basis of indandione inhibitor disruption of binding between HPV11 E2 protein transactivation domain and E1 helicase)
RN 681294-53-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-5-yl)phenyl]amino]carbonyl]-, (2R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:891609 CAPLUS
DOCUMENT NUMBER: 140:104529
TITLE: Structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction
AUTHOR(S): Yoakim, Christiane; Goudreau, Nathalie; McGibbon, Graham A.; O'Meara, Jeff; White, Peter W.; Ogilvie, William W.
CORPORATE SOURCE: Research & Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Helvetica Chimica Acta (2003), 86(10), 3427-3444
CODEN: HCACAV; ISSN: 0018-019X
PUBLISHER: Verlag Helvetica Chimica Acta
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel series of inhibitors of the HPV11 E1-E2 protein-protein interaction was identified. These inhibitors, which were discovered as a result of high-throughput screening, feature an indandione system spirofused onto an appropriately substituted THF ring. Early stability studies indicated, surprisingly, that this particular series of compds. were readily converted, in binding assay buffer, to the corresponding carboxylates. NMR and mass spectrometry techniques were used to elucidate the structures of these products and the mechanism by which they are produced.

IT 439122-86-8P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction)
RN 439122-86-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

IT 439122-96-0P 647037-99-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(structure elucidation of the first inhibitors of human papillomavirus type 11 E1-E2 protein-protein interaction)
RN 439122-96-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 647037-99-8 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:58117 CAPLUS
DOCUMENT NUMBER: 138:119829
TITLE: Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
INVENTOR(S): Cameron, Dale R.; Archambault, Jacques; Yoakim, Christiane; White, Peter
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Wang, Yong
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006495	A2	20030123	WO 2002-CA1058	20020712
WO 2003006495	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003082769	A1	20030501	US 2002-193460	20020711
CA 2448482	AA	20030123	CA 2002-2448482	20020712
EP 1409525	A2	20040421	EP 2002-745024	20020712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005512954	T2	20050512	JP 2003-512265	20020712
PRIORITY APPLN. INFO.:			US 2001-304412P P	20010712
			WO 2002-CA1058 W	20020712

AB A crystallizable composition, comprising an PV E2 TAD-like polypeptide complexed with an inhibitor L is claimed. The invention also provides a method for producing the crystallized HPV E2 TAD-inhibitor complex (HPV E2 TAD-L) comprising: a) mixing purified HPV E2 TAD, contained in a purification buffer, with solubilized inhibitor L to generate a complex solution containing the HPV E2 TAD-L complex and b) crystallizing the complex from a) in a crystallization buffer. The invention also provides a method for producing crystallized apo HPV E2 TAD, comprising: a) mixing apo HPV E2 TAD, contained in a purification buffer, with a crystallization buffer. X-ray crystal structure coordinates of the HPV E2 TAD-L complex are also provided, which define an inhibitor binding pocket. The inhibitor binding pocket is useful for screening potential small mol. inhibitors that bind to the pocket.

IT 487060-68-4P
RL: BUU (Biological use, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket)

RN 487060-68-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 487060-71-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of human papillomavirus E2 protein transactivation domain inhibitor)

RN 487060-71-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:487569 CAPLUS
DOCUMENT NUMBER: 137:63181
TITLE: Preparation of spiroheterocycles for therapeutic use as papilloma virus inhibitors
INVENTOR(S): Yoakim, Christiane; Hache, Bruno; Ogilvie, William W.; O'Meara, Jeffrey; White, Peter; Goudreau, Nathalie
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050082	A2	20020627	WO 2001-CA1800	20011214
WO 2002050082	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430909	AA	20020627	CA 2001-2430909	20011214
AU 2002018897	A5	20020701	AU 2002-18897	20011214
EP 1345943	A2	20030924	EP 2001-271377	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004515555	T2	20040527	JP 2002-551975	20011214
US 2003064985	A1	20030403	US 2001-23975	20011217
US 6759409	B2	20040706		
US 2005009855	A1	20050113	US 2004-772721	20040204
PRIORITY APPLN. INFO.:			US 2000-256706P	P 20001218
			WO 2001-CA1800	W 20011214
			US 2001-23975	A3 20011217

OTHER SOURCE(S): MARPAT 137:63181
GI

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Spiroheterocycles, such as I [R1 = H, Me, F, etc.; R3 = alkyl, cycloalkyl, alkylene, aryl, etc.; R4 = carboxylic acid, salt or ester; X = H, W = OH; XW = O, OCH2; Y = Ph, aryl, heteroaryl;], were prepared for pharmaceutical use in the treatment or prevention of human papilloma virus infection. Thus, "cis/cis"-spiroheterocycle II was prepared via a multistep synthetic sequence starting from indan-1,3-dione, 3,4-dichlorobenzaldehyde, and 1-(1,3-benzodioxol-5-yl)-1H-pyrrole-2,5-dione. The prepared spiroheterocycles were assayed for E2-dependent E1 DNA binding, SV40 T antigen-DNA binding, and cell-based DNA replication.

IT 439122-77-7P 439122-78-8P 439122-79-9P
439122-80-2P 439122-81-3P 439122-83-5P
439122-84-6P 439122-86-8P 439122-87-9P
439122-89-1P 439122-96-0P 439123-00-9P
439123-02-1P 439123-03-2P 439123-07-6P
439123-08-7P 439123-09-8P 439123-10-1P
439123-13-4P 439123-26-9P 439123-29-2P
439123-30-5P 439123-31-6P 439123-32-7P
439123-33-8P 439123-34-9P 439123-38-3P
439123-44-1P 439123-45-2P 439123-47-4P
439123-49-6P 439123-51-0P 439123-53-2P
439123-55-4P 439123-57-6P 439123-60-1P
439123-62-3P 439123-63-4P 439123-65-6P
439123-67-8P 439123-68-9P 439123-70-3P
439123-72-5P 439123-74-7P 439123-75-8P
439123-76-9P 439123-78-1P 439123-79-2P
439123-80-5P 439123-82-7P 439123-83-8P
439123-84-9P 439123-88-3P 439123-89-4P
439123-90-7P 439123-91-8P 439123-92-9P
439123-93-0P 439123-94-1P 439123-95-2P
439123-96-3P 439123-97-4P 439123-98-5P
439124-00-2P 439124-02-4P 439124-04-6P
439124-05-7P 439124-06-8P 439124-07-9P
439124-08-0P 439124-10-4P 439124-12-6P
439124-14-8P 439124-16-0P 439124-18-2P
439124-21-7P 439124-23-9P 439124-25-1P
439124-31-9P 439124-33-1P 439124-35-3P
439124-39-7P 439124-45-5P 439124-47-7P
439124-49-9P 439124-51-3P 439124-53-5P
439124-54-6P 439124-56-8P 439124-57-9P

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

439124-58-0P 439124-59-1P 439124-60-4P
439124-61-5P 439124-62-6P 439124-63-7P
439124-64-8P 439124-67-1P 439125-18-5P
439125-24-3P 439125-30-1P 439125-32-3P
439125-37-8P 439125-39-0P 439125-47-0P
439125-49-2P 439125-51-6P 439125-53-8P
439125-55-0P 439125-57-2P 439125-59-4P
439125-61-8P 439125-63-0P 439125-71-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiroheterocycles for therapeutic use as papilloma virus inhibitors)

RN 439122-77-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[(4-fluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-78-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[(3,4-dimethoxyphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439122-79-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-80-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[(3-chlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-,

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439122-83-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[(2,4-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-84-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-4-[[(4-chlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-81-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-4-[[(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



● Na

RN 439122-86-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-87-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-4-[[(3-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439122-89-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(4-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439122-96-0 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-02-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-03-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(6-methyl-2-benzothiazolyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-00-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● Na

RN 439123-07-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3-chlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-08-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-09-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-13-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-26-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[(4-phenoxyphenyl)amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-10-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-(acetylamino)phenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-29-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-30-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439123-31-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-cyclohexylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-32-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(4-ethylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439123-34-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-(benzoylamino)phenyl]amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-38-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-44-1 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439123-33-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dimethylphenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439123-45-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-chlorophenyl)amino]carbonyl]-5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439123-45-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-chlorophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-47-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-49-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-51-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-[3-fluoro-4-(trifluoromethyl)phenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-53-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-55-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5'-bromo-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-57-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-cyanophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



● Na

RN 439123-60-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-62-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-63-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[(phenylamino)carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-65-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-67-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-68-9 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-70-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylthio)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-72-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-74-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-cyanophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-75-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(methylsulfonyl)phenyl]amino]carbonyl]-1',3'-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-76-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-(2-methyl-5-benzofuranyl)-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-78-1 CAPLUS
CN Spiro[2H-benz[f]indene-2,2'(3'H)-furan]-3'-carboxylic acid, 4'-[[(4-acetylphenyl)amino]carbonyl]-5'-(3,4-dichlorophenyl)-1,3,4',5'-tetrahydro-1,3-dioxo-, monosodium salt, (3'R,4'S,5'R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



● Na

RN 439123-82-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-83-8 CAPLUS
CN Spiro[2H-benz[e]indene-2,2'(3'H)-furan]-3'-carboxylic acid,

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



● Na

RN 439123-79-2 CAPLUS
CN Spiro[2H-benz[e]indene-2,2'(3'H)-furan]-3'-carboxylic acid, 4'-[[(4-acetylphenyl)amino]carbonyl]-5'-(3,4-dichlorophenyl)-1,3,4',5'-tetrahydro-1,3-dioxo-, monosodium salt, (2R,3'S,4'R,5'S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-80-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[4-(acetylamino)phenyl]amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
4'-[[(4-acetylphenyl)amino]carbonyl]-5'-(3,4-dichlorophenyl)-1,3,4',5'-tetrahydro-1,3-dioxo-, monosodium salt, (2R,3'R,4'S,5'R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-84-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(3,5-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-88-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(3-benzoylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-89-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-bromo-3-chlorophenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-90-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(3-benzoylphenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-91-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-bromo-3-chlorophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-92-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[(3,4-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-93-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-5'-fluoro-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-94-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-5'-fluoro-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-95-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[(3,5-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439123-96-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[[(4-chlorophenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439123-97-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(3,4-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439123-98-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-00-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5'-chloro-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-02-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5'-chloro-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439124-04-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-05-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(3-chlorophenyl)amino]carbonyl]-5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-06-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-4-[[(3,5-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-07-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-bromo-3-chlorophenyl)amino]carbonyl]-5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439124-08-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-4-[[(3,4-difluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-10-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(2-chlorophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439124-12-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[(2-methoxyphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-14-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(2-fluorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439124-16-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(3,5-dimethylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-18-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(3-cyanophenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



● Na

RN 439124-21-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methoxy-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-31-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-difluorophenyl)-1',3',4,5-tetrahydro-4-[[(4-methylphenyl)amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-33-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(2,3-dimethylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-23-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methoxy-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-25-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3-chloro-4-fluorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



● Na

RN 439124-35-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-4-[[(3,4-dichlorophenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-39-7 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-4-[[(2-ethoxyphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-45-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-4-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-47-7 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-51-3 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(2-bromophenyl)amino]carbonyl]-5-(3,5-dichlorophenyl)-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-53-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-4-[[[4-[[[2-[methyl[2-[methyl(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethyl]amino]-2-oxoethyl]amino]methyl]phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● Na

RN 439124-49-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-[4-chloro-3-[(1-oxopentyl)amino]phenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439124-54-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 439124-56-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



RN 439124-57-9 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dichlorophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-58-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439124-60-4 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-61-5 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-6'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3S,4R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-59-1 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-5'-methyl-1',3'-dioxo-4-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]amino]carbonyl]-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 439124-62-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-5'-fluoro-1',3',4,5-tetrahydro-6'-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, monosodium salt, (2'R,3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-63-7 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-8-methyl-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-64-8 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439124-67-1 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-8-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439125-18-5 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(2-chlorophenyl)-2-(4-chlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439125-32-3 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-7-methyl-4,10-dioxo-N-[4-(1,2,3-thiadiazol-4-yl)phenyl]-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439125-37-8 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-8-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 439125-24-3 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439125-30-1 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(4-acetylphenyl)-2-(3-chloro-1H-indol-2-yl)-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 439125-39-0 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, 2-(3,4-dibromophenyl)-7-fluoro-2,3,3a,4,5a,10-hexahydro-5a-hydroxy-N-[4-(4-morpholinyl)phenyl]-4,10-dioxo-, (2R,3S,3aR,5aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 439125-47-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-(2-naphthalenyl)-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 439125-49-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-[(1E)-2-phenylethenyl]-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-51-6 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-[(1E)-2-(3-bromophenyl)ethenyl]-1',3',4,5-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 439125-55-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-1',3'-dioxo-5-[(1E)-2-phenyl-1-propenyl]-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-57-2 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-[(1E)-1-methyl-2-phenylethenyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-59-4 CAPLUS

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-53-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-[(1E)-2-(2-bromophenyl)ethenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-5-[(1E)-2-(2,3-dichlorophenyl)ethenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-61-8 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-acetylphenyl)amino]carbonyl]-1',3',4,5-tetrahydro-5-[(1E)-2-(2-methylphenyl)ethenyl]-1',3'-dioxo-, monosodium salt, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-63-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 4-[[(4-

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
acetylphenyl]amino]carbonyl]-5-[(1Z)-1-bromo-2-phenylethenyl]-1',3',4,5-tetrahydro-1',3'-dioxo-, monosodium salt, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

RN 439125-71-0 CAPLUS
CN Spiro[furan-2(3H),2'-[2H]indene]-3-carboxylic acid, 5-(3,4-dibromophenyl)-1',3',4,5-tetrahydro-4-[[[4-(4-morpholinyl)phenyl]amino]carbonyl]-1',3'-dioxo-, (3R,4S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:210177 CAPLUS
DOCUMENT NUMBER: 132:222527
TITLE: Preparation of tetracyclic heterocycles as bactericides and medical fungicides
INVENTOR(S): Finn, John; Yu, Xiang Yang; Wang, Zhongguo; Hill, Jason; Keith, Dennis; Gallant, Paul; Wendler, Philip
PATENT ASSIGNEE(S): Cubist Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017206	A1	20000330	WO 1999-US20930	19990910
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9958220	A1	20000410	AU 1999-58220	19990910
US 6153645	A	20001128	US 1999-393505	19990910
PRIORITY APPLN. INFO.:			US 1998-100809P P	19980918
			US 1998-102695P P	19981001
			WO 1999-US20930 W	19990910

OTHER SOURCE(S): MARPAT 132:222527
GI



I



II

AB Title compds. [I; A = O, SO0-2, NR3 OCR4R5, NR3CR4R5, etc.; B = (alkyl)iminocarbonyl or O2C; D = H or (hetero)aryl; M = H, alkyl, aryl, CO2H, etc.; MD = CR:CRC(:V), CR:CRCHE; E = H, OH, halo, NH2, alkoxy, aryloxy; RR = (un)substituted CH:CHCH:CH, -CH:CHCHN, -CH:CHN:CH, etc.; R1,R2 = (hetero)aryl; R3 = H, alkyl, carboalkoxy (sic), carboxyamido (sic); V, W = O, S, NR13, NOR13, NNHR13; X,Y = CH or N; Z = O, NR6, CR7R8; R4-R8,R13 = H or alkyl], aminoacyl-tRNA synthetase inhibitors, were prepared Thus, 3-phenylspiro[oxirane-2,2'-indan-1',3'-dione] was cyclocondensed with N-(3,4-dichlorophenyl)maleimide (preparation each given) and the product
cyclized to give title compound II. Data for biol. activity of I were given.
IT 261157-65-7P

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetracyclic heterocycles as bactericides and medical fungicides)
RN 261157-65-7 CAPLUS
CN Furo[2,3-c]indeno[1,2-b]furan-3-carboxamide, N-(3,4-dichlorophenyl)-2,3,3a,4,5a,10-hexahydro-4,10-dioxo-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT